Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

Pharmaceutical giant Novavax on Monday announced that the U.S. Food and Drug Administration (FDA) approved its COVID-19 ...

Key Takeaways Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine.The shot, ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

US health regulators have given final approval to Novavax's COVID vaccine after an unusual delay and have placed new ...

Novavax (NASDAQ:NVAX) shares jumped more than 17% on Monday after the U.S. Food and Drug Administration granted full approval ...

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

Nuvaxovid is a recombinant protein-based COVID ... Jacobs, President and Chief Executive Officer, Novavax. Along with the approval, the FDA also requested Novavax conduct a phase 4 randomized ...

The U.S. Food and Drug Administration approved Novavax's Covid-19 vaccine with age restrictions after a six-week delay.